<DOC>
	<DOC>NCT02112526</DOC>
	<brief_summary>To characterize the safety profile of ACP-196 in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).</brief_summary>
	<brief_title>ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<criteria>Men and women ≥ 18 years of age. Pathologically confirmed de novo ABC DLBCL Relapsed or refractory disease Subjects must have ≥ 1 measurable disease sites A lifethreatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP196, or put the study outcomes at undue risk Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF &gt; 50% Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Breast feeding or pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Novo Activated B-cell (ABC)</keyword>
	<keyword>Novo Activated B-cell</keyword>
	<keyword>ABC DLBCL</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>B-Cell</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>